A wave of biopharma investment brings new jobs to Virginia

A message from: PhRMA – Pharmaceutical Research and Manufacturers of America

PhRMA
Biopharmaceutical manufacturing is driving major job creation, investment and economic activity across Virginia.
PhRMA member companies AstraZeneca, Eli Lilly and Company and Merck are investing a combined $12.5 billion in manufacturing projects, bringing new facilities and jobs to communities across the Commonwealth:
- Near Charlottesville: AstraZeneca is investing $4.5 billion in a manufacturing facility expected to create approximately 600 highly skilled jobs and 3,000 construction jobs. The site will manufacture drug substances for medicines across the company's weight-management, metabolic and cancer portfolios.
- Near Richmond: Lilly plans to invest $5 billion in a Goochland County facility that will manufacture active pharmaceutical ingredients and drug products for cancer, autoimmune diseases and other advanced therapies. The project is expected to create 650 permanent jobs and 1,800 construction jobs.
- In Elkton: Merck has been manufacturing medicines in VA for more than 80 years, and its latest $3 billion investment in a new 400,000-square-foot Center of Excellence for Pharmaceutical Manufacturing builds on that longstanding manufacturing legacy in the Commonwealth. The facility will support small-molecule manufacturing and testing and could create more than 500 full-time roles and 8,000 construction jobs.
Key numbers: Together, the three projects are expected to create more than 1,700 permanent jobs and more than 12,000 construction jobs.
These projects build on an industry that's already growing fast in Virginia.
- Direct biopharma jobs in the Commonwealth grew by almost 5K jobs by 2024, one of the top five gains in the country, according to new research by TEConomy Partners prepared for PhRMA.
- The industry supports almost 65,000 total jobs, including over 16,000 direct biopharma jobs, and generates $20.3 billion in economic output across the Commonwealth.
- And that data doesn't yet reflect the latest wave of investments announced in 2025.
Why it's important: These are good jobs, and their impact reaches well beyond the plant floor.
- Biopharma jobs pay more than the state average in every state, including Virginia.
- Every biopharma job in Virginia supports about three more jobs elsewhere in the Commonwealth's economy.
Speaking at a recent Axios event in Richmond, Elizabeth Carpenter, executive vice president of policy and research at PhRMA, highlighted the broader economic impact of Virginia's growing biopharmaceutical workforce.
- "Virginia is a great example. We actually released new research this morning that shows biopharmaceutical jobs in Virginia have grown 40% between 2022 and 2024. And when you think about those jobs, there's really a few important things to note. One, they're really good jobs — These are jobs that have wages that are higher than the state average. Also, they are jobs that really multiply and feed an economy."
The workforce opportunity is clear: Every new facility needs a skilled team to run it.
- Scientists, engineers, technicians and operators will all play a role, with long-term career paths in a sector built on advanced technology, precision production and rigorous quality standards.
- The AstraZeneca Virginia facility, for example, will leverage AI, automation and data analytics to optimize production.
- Construction jobs bring near-term opportunity to local communities, while permanent roles anchor high-value employment for years to come.
The impact: Virginia is showing how states can compete and win in the life sciences.
- The Commonwealth has built on its strengths in talent, research, infrastructure and its business climate, with leaders across government, higher education and industry working together to attract investment and create high-quality jobs.
- Lilly, for example, cited workforce potential, utilities, transportation, zoning and incentives in selecting Goochland County. The project is also supported through the Virginia Talent Accelerator Program.
- That sustained commitment, backed by a stable, predictable policy environment, sends an important signal to companies deciding where to invest next.
Here's what else: Virginia's growth is part of a bigger story about U.S. biopharmaceutical leadership.
- When America leads, American patients benefit. U.S. patients can access 88% of new medicines, compared with 36% in other high-income countries, and get them an average of three years sooner, according to PhRMA.
- Sustaining that leadership takes strong IP protections, efficient regulation and market-based incentives, along with the skilled workers and infrastructure to develop and manufacture medicines at scale.
The takeaway: Biopharma manufacturing investments in Virginia are creating opportunities that extend across the Commonwealth. New facilities are supporting high-value jobs, new career paths and a workforce prepared for the next generation of medicine manufacturing.